ID

34335

Descrição

Combination Treatment for Advanced Liver Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02149771

Link

https://clinicaltrials.gov/show/NCT02149771

Palavras-chave

  1. 16/01/2019 16/01/2019 -
  2. 26/04/2020 26/04/2020 -
  3. 01/05/2020 01/05/2020 -
  4. 20/09/2021 20/09/2021 -
Titular dos direitos

see on clinicaltrials.gov

Transferido a

16 de janeiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Hepatocellular Carcinoma NCT02149771

Eligibility Hepatocellular Carcinoma NCT02149771

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
Descrição

ID.1

Tipo de dados

boolean

(2) child-pugh classification grade a or b;
Descrição

ID.2

Tipo de dados

boolean

(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
Descrição

ID.3

Tipo de dados

boolean

Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
Descrição

ID.4

Tipo de dados

boolean

tumor invade the inferior vena cava, extrahepatic spread;
Descrição

ID.5

Tipo de dados

boolean

contraindications for doxorubicin or oxaliplatin chemotherapy;
Descrição

ID.6

Tipo de dados

boolean

any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
Descrição

ID.7

Tipo de dados

boolean

renal failure,cardiac ejection fraction <50 %) or end-stage disease;
Descrição

ID.8

Tipo de dados

boolean

patients who were not capable of cooperation during the procedure.
Descrição

ID.9

Tipo de dados

boolean

Similar models

Eligibility Hepatocellular Carcinoma NCT02149771

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
boolean
ID.2
Item
(2) child-pugh classification grade a or b;
boolean
ID.3
Item
(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
boolean
ID.5
Item
tumor invade the inferior vena cava, extrahepatic spread;
boolean
ID.6
Item
contraindications for doxorubicin or oxaliplatin chemotherapy;
boolean
ID.7
Item
any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
boolean
ID.8
Item
renal failure,cardiac ejection fraction <50 %) or end-stage disease;
boolean
ID.9
Item
patients who were not capable of cooperation during the procedure.
boolean

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial